Wall Street analysts predict that Imperva Inc (NYSE:IMPV) will post ($0.59) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Six analysts have provided estimates for Imperva’s earnings. Imperva posted earnings per share of ($0.76) during the same quarter last year, which indicates a positive year over year growth rate of 22.4%. The business is expected to report its next earnings results after the market closes on Thursday, July 27th.

On average, analysts expect that Imperva will report full year earnings of ($1.46) per share for the current financial year. For the next financial year, analysts expect that the company will report earnings of ($1.71) per share. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Imperva.

Imperva (NYSE:IMPV) last released its quarterly earnings results on Thursday, May 4th. The software maker reported ($0.29) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.62) by $0.33. The firm had revenue of $72.31 million during the quarter, compared to analysts’ expectations of $68.16 million. Imperva had a return on equity of 36.67% and a net margin of 31.92%. The business’s revenue was up 21.0% on a year-over-year basis. During the same period last year, the firm posted ($0.25) EPS.

IMPV has been the topic of a number of research analyst reports. UBS AG initiated coverage on shares of Imperva in a research report on Tuesday, June 6th. They set a “positive” rating and a $60.00 price target on the stock. Stephens reaffirmed an “overweight” rating and set a $61.00 price target (up previously from $53.00) on shares of Imperva in a research report on Thursday, July 13th. Stifel Nicolaus reaffirmed a “hold” rating and set a $47.00 price target on shares of Imperva in a research report on Friday, July 14th. BidaskClub cut shares of Imperva from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 5th. Finally, ValuEngine cut shares of Imperva from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and thirteen have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $50.29.

In other Imperva news, insider Amichai Shulman sold 3,089 shares of the stock in a transaction dated Monday, May 15th. The shares were sold at an average price of $48.70, for a total value of $150,434.30. Following the completion of the sale, the insider now owns 100,151 shares in the company, valued at approximately $4,877,353.70. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CRO Michael D. Mooney sold 52,356 shares of the stock in a transaction dated Wednesday, May 10th. The shares were sold at an average price of $47.51, for a total transaction of $2,487,433.56. Following the completion of the sale, the executive now owns 52,356 shares of the company’s stock, valued at approximately $2,487,433.56. The disclosure for this sale can be found here. Insiders sold a total of 60,302 shares of company stock worth $2,875,861 in the last 90 days. 2.20% of the stock is currently owned by company insiders.

A number of large investors have recently bought and sold shares of IMPV. Vanguard Group Inc. raised its stake in Imperva by 4.6% in the first quarter. Vanguard Group Inc. now owns 2,339,441 shares of the software maker’s stock valued at $96,033,000 after buying an additional 102,779 shares during the period. JPMorgan Chase & Co. raised its stake in Imperva by 2.2% in the first quarter. JPMorgan Chase & Co. now owns 1,627,998 shares of the software maker’s stock valued at $66,828,000 after buying an additional 34,653 shares during the period. Clearbridge Investments LLC raised its stake in Imperva by 47.0% in the first quarter. Clearbridge Investments LLC now owns 1,262,507 shares of the software maker’s stock valued at $51,826,000 after buying an additional 403,809 shares during the period. Eagle Asset Management Inc. raised its stake in Imperva by 4.1% in the first quarter. Eagle Asset Management Inc. now owns 1,087,223 shares of the software maker’s stock valued at $44,630,000 after buying an additional 43,278 shares during the period. Finally, North Run Capital LP raised its stake in Imperva by 999.3% in the first quarter. North Run Capital LP now owns 750,000 shares of the software maker’s stock valued at $30,788,000 after buying an additional 681,772 shares during the period. Hedge funds and other institutional investors own 92.72% of the company’s stock.

WARNING: This report was posted by American Banking News and is the property of of American Banking News. If you are viewing this report on another website, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/07/19/0-59-earnings-per-share-expected-for-imperva-inc-nyseimpv-this-quarter.html.

Shares of Imperva (NYSE:IMPV) remained flat at $51.80 on Wednesday. 250,953 shares of the company’s stock were exchanged. Imperva has a 52-week low of $34.40 and a 52-week high of $57.24. The firm’s market capitalization is $1.73 billion. The firm’s 50-day moving average price is $49.23 and its 200 day moving average price is $44.60.

About Imperva

Imperva, Inc provides cyber-security solutions that protect business-critical data and applications whether in the cloud or on premises. The Company is engaged in the development, marketing, sales, service and support of cyber-security solutions. The Company’s products include its Imperva SecureSphere Paltform, Imperva CounterBreach and Imperva Camouflage for enterprise data centers, and Imperva Incapsula offering for cloud-based security services.

Get a free copy of the Zacks research report on Imperva (IMPV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Imperva Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva Inc and related companies with MarketBeat.com's FREE daily email newsletter.